NP90323(c) Botulinum Toxin Type A Medicines (Xeomin®)
A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £3M
- Sector
- HEALTH
- Published
- 04 Oct 2023
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014
1 buyer
- NHS National Services Scotland NSS Edinburgh
1 supplier
- Merz Pharma Herts
Description
Supply of Botulinum Toxin Type A Medicines(Xeomin®) to NHS Scotland: NP90323(c): Botulinum Toxin Type A Injection 50-unit vial/ Botulinum Toxin Type A Injection 100-unit vial/ Botulinum Toxin Type A Injection 200-unit vial (Xeomin®)
Total Quantity or Scope
The Framework Agreement is for the supply of Botulinum Toxin Type A (Xeomin®) to NHS Scotland. The Framework Agreement has been awarded as a Single supplier framework agreement to one (1) Framework Participant.
Award Detail
| 1 | Merz Pharma (Herts)
|
CPV Codes
- 33600000 - Pharmaceutical products
Legal Justification
The medicine to be awarded to the framework agreement is protected by exclusive rights, including intellectual property rights, in line with Regulation 33(1)(b)(iii) of the Public Contracts (Scotland) Regulations 2015.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value(s) of the Framework Agreement referred to in Sections II.1.7 and V.2.4 cover(s) the thirty-six (36) month contract duration and the twelve (12) month extension period of the Framework Agreement. (SC Ref:743081)
Reference
- ocds-h6vhtk-0407c5
- FTS 029230-2023